Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk

Starting soon · Not applicable

Conditions studied: Non-Small Cell Lung Cancer, Recurrence, Survival Analysis

In brief

The goal of this clinical trial is to explore if perioperative lidocaine infusion decreases disease reoccurrence and metastasis risk in non-small cell lung cancer patients. Participants will be randomly assigned (1:1) to the lidocaine or placebo group. The intervention initiates within 30 minutes before anesthesia induction with an intravenous loading dose of 1.5 mg/kg administered over 10-20 minutes. This is followed by a continuous maintenance infusion of 1.5-3 mg/kg/h (calculated as 1-1.5 mg/kg/h in protocol text, see note below) during surgery, terminating 1 hour after skin closure. Participants will be followed up for 36 months post-surgery. Blood samples will be collected at baseline, postoperative day 1, day 3, and upon discharge

Key facts

Study ID

NCT07347977

Run by

First Affiliated Hospital of Ningbo University

People needed

1400

Starts

2026-01-01

Expected to finish

2029-12-30

Last updated by the study team

2026-01-16

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age range: 18-80 years old.
• Electively undergo minimally invasive (thoracoscopic or robotic) surgery for the treatment of lung cancer
• Is willing and capable of providing consent.

You may not qualify if…

• Palliative surgery without intention of cure.
• Extensive comorbidities (ASA IV).
• Patients with known or suspected allergy to lidocaine.
• Patients who are currently pregnant or breastfeeding.
• Patients who may experience adverse reactions due to accumulation of lidocaine during intravenous infusion, as stated in the Summary of Product Characteristics (SmPC) for lidocaine.
• Currently, there is abnormal liver function, with ALT or AST levels exceeding the laboratory reference range by a factor of 2.
• Currently, there is severe renal insufficiency (serum creatinine ≥451umol/L or glomerular filtration rate (calculated using the MDRD formula) <30ml/min).
• Epilepsy.
• Patients with cardiac conduction abnormalities, including second-degree or third-degree heart block without a pacemaker, left bundle branch block, sick sinus syndrome, and pre-excitation syndrome (confirmed by medical history and electrocardiogram), as well as those with low cardiac output due to reduced left ventricular ejection fraction.
• Concurrent use with continuous infusion of other local anesthetic drugs (such as epidural).
• Patients who use drugs that may cause reasons for exclusion, including Class I and Class III antiarrhythmic drugs (such as mexiletine and amiodarone), cimetidine, and antiviral drugs. Eligibility will be determined by local clinicians and verified by clinical trial doctors.
• Patients with body weight <40kg

Where it is running

• The first affiliated hospital of Ningbo University — Ningbo, Zhejiang, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.